ES2037660T3 - Procedimiento para preparar derivados de imidazopiridina condensados. - Google Patents

Procedimiento para preparar derivados de imidazopiridina condensados.

Info

Publication number
ES2037660T3
ES2037660T3 ES198686308087T ES86308087T ES2037660T3 ES 2037660 T3 ES2037660 T3 ES 2037660T3 ES 198686308087 T ES198686308087 T ES 198686308087T ES 86308087 T ES86308087 T ES 86308087T ES 2037660 T3 ES2037660 T3 ES 2037660T3
Authority
ES
Spain
Prior art keywords
radical
alkylic
halogen
alkyl
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198686308087T
Other languages
English (en)
Inventor
Susumu Takada
Toshio Fujishita
Takashi Sasatani
Akira Matsushita
Masami Eigyo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of ES2037660T3 publication Critical patent/ES2037660T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

DONDE R ES UN GRUPO FENILO CON UNO O DOS SUSTITUYENTES DE ENTRE LOS SIGUIENTES: TRIFLUOROMETIL, RADICAL ALQUILICO C1-5, RADICAL ALCOXILICO C1-5, RADICAL TIOALPULICO C1-5, NITRO, RADICAL AMINO ALPULICO C1-5 Y RADICAL ALCOXICARBONIL C1-5 O UN GRUPO HETEROCICLICO DE 5 O 6 MIEMBROS OPCIONALMENTE SUSTITUIDO POR UNO DE LOS SIGUIENTES GRUPOS: HALOGENO, RADICAL ALQUILICO C1-5 Y RADICAL ALCOXILICO C1-5, Q: ES H, RADICAL ALQUILICO C1-5, RADICAL ACICLICO C1-10, RADICAL SULFONIALQUILICO C1-5 O RADICAL SULFONILARILO C5-10. R1, R2, R3 Y R4 SON H, HALOGENO, ALQUILICO C1-C5 O ALQUILHALOGENO C1-C5. Q ESTA UNIDO AL N DE LAS POSICIONES 1,3 O 5 Y LA LINEA DE PUNTOS INDICA LA PRESENCIA DE TRES DOBLES ENLACES EN LA POSICION 2,3; 3A,3B; 4,5; 1,3B; 2,3; 3A,4 O 1,2; 3A,3B; 4,5. ESTOS COMPUESTOS Y SUS SALES SON UTILES COMO PSICOESTIMULANTES O ANXIOLITICOS.
ES198686308087T 1985-10-18 1986-10-17 Procedimiento para preparar derivados de imidazopiridina condensados. Expired - Lifetime ES2037660T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23435785 1985-10-18
JP11968186 1986-05-23

Publications (1)

Publication Number Publication Date
ES2037660T3 true ES2037660T3 (es) 1993-07-01

Family

ID=26457370

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198686308087T Expired - Lifetime ES2037660T3 (es) 1985-10-18 1986-10-17 Procedimiento para preparar derivados de imidazopiridina condensados.

Country Status (8)

Country Link
US (1) US4753951A (es)
EP (1) EP0223420B1 (es)
KR (1) KR910001136B1 (es)
AU (1) AU599340B2 (es)
CA (1) CA1306260C (es)
DE (1) DE3677711D1 (es)
ES (1) ES2037660T3 (es)
GB (1) GB2182930B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335996C (en) * 1988-02-16 1995-06-20 Susumu Takada 2-substituted carbonylimidazo¬4,5-c|quinolines
US5019574A (en) * 1988-09-30 1991-05-28 Chugai Seiyaku Kabushiki Kaisha 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function
EP0385630B1 (en) * 1989-02-27 1996-11-27 Riker Laboratories, Inc. 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals
US5003103A (en) * 1989-11-20 1991-03-26 Occidental Chemical Corporation Preparation of 2-choloro-4,5-difluorobenzoic acid from 4,5-difluorophthalic anhydride of 4,5-difluorophthalic acid
US4937377A (en) * 1989-11-20 1990-06-26 Occidental Chemical Corporation Preparation of 3,4-difluorobenzoic acid by the decarboxylation of 4,5-difluorophthalic anhydride or 4,5-difluorophthalic acid
US5342843A (en) * 1991-12-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Thienoimidazoppyridone derivatives
US5378848A (en) * 1992-02-12 1995-01-03 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
NZ507760A (en) 1998-03-26 2002-10-25 Japan Tobacco Inc Amide derivatives and nociceptin antagonists
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20040192728A1 (en) * 2003-02-03 2004-09-30 Ellen Codd Quinoline-derived amide modulators of vanilloid VR1 receptor
BRPI0413558A (pt) 2003-08-12 2006-10-17 3M Innovative Properties Co compostos contendo imidazo substituìdo por hidroxilamina
AU2004268625B2 (en) 2003-08-27 2011-03-31 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
AU2004270201A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
EP1685129A4 (en) 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
JP2007517035A (ja) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
EP1699788A2 (en) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US20070259881A1 (en) * 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006032851A1 (en) * 2004-09-20 2006-03-30 Biolipox Ab Pyrazole compounds useful in the treatment of inflammation
JP5543068B2 (ja) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
EP1831221B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Substituted chiral fused 1,2 imidazo 4,5-c ring compounds
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
US7683171B2 (en) * 2005-02-04 2010-03-23 Bristol-Myers Squibb Company 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
CA2789262C (en) 2005-04-28 2016-10-04 Proteus Digital Health, Inc. Pharma-informatics system
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
EP1943234A1 (en) * 2005-10-31 2008-07-16 Biolipox AB Triazole compounds as lipoxygenase inhibitors
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
JP2009513692A (ja) * 2005-11-01 2009-04-02 バイオリポックス エービー 炎症の治療に有用なピラゾール化合物
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
TR201908314T4 (tr) 2009-02-20 2019-06-21 2 Bbb Medicines B V Glutatyon bazlı ilaç dağıtım sistemi.
KR101909711B1 (ko) 2009-05-06 2018-12-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
TWI646099B (zh) * 2012-11-01 2019-01-01 英塞特控股公司 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
MA39987A (fr) 2014-04-30 2017-03-08 Incyte Corp Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
WO2020083662A1 (en) * 2018-10-23 2020-04-30 Basf Se Tricyclic pesticidal compounds
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE238235C (es) *
US509588A (en) 1893-11-28 Car-coupling
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
CA1263651A (en) * 1984-07-09 1989-12-05 Ciba-Geigy Ag Certain ring-fused pyrazolo ¬3,4-d|-pyridin-3-one derivatives
US4775674A (en) * 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors

Also Published As

Publication number Publication date
AU599340B2 (en) 1990-07-19
EP0223420B1 (en) 1991-02-27
GB8624939D0 (en) 1986-11-19
AU6416586A (en) 1987-04-30
GB2182930A (en) 1987-05-28
KR870004030A (ko) 1987-05-07
DE3677711D1 (de) 1991-04-04
CA1306260C (en) 1992-08-11
GB2182930B (en) 1989-09-27
EP0223420A1 (en) 1987-05-27
KR910001136B1 (ko) 1991-02-25
US4753951A (en) 1988-06-28

Similar Documents

Publication Publication Date Title
ES2037660T3 (es) Procedimiento para preparar derivados de imidazopiridina condensados.
ES2062460T3 (es) Nuevos derivados de la isoindolona, su preparacion y las composiciones farmaceuticas que les contienen.
ES2103786T3 (es) Derivados de 4-benzoil-isoxazol.
BR7604880A (pt) Corrente de elos com juntas esfericas
PE10090A1 (es) Tiazoles substituidos y su uso como fungicidas
ES2163410T3 (es) Derivados de benzodiazepina.
NO900279L (no) Alkylerte polyetyleniminderivater og fremgangsmaate for fremstilling derav samt anvendelse av derivatene.
ES2083569T3 (es) Nuevos derivados de ariletenileno y procedimiento para su preparacion.
ES2075648T3 (es) Composicion para frenar la caida de los cabellos, y para inducir y estimular su crecimiento, a base de derivados de pirimidinas-n-oxido trisustituidas en las posiciones 2, 4 y 6 por una funcion amina, y nuevos compuestos de pirimidina-n-oxido.
ES2011210T3 (es) Derivados de gem-difosfonato substituido, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2166379T3 (es) 2-aminotetralinas sustituidas.
SE8303502L (sv) Karbapenem-antibiotika
ES2158840T3 (es) Nuevos analogos de adenosina carbociclicos utiles como inmunosupresores.
ES2038766T3 (es) 4-aril-5-carbamoil-1,4-dihidropiridinas.
SE416298B (sv) Forfarande for framstellning av nya bensimidazolinon derivat
DE3778396D1 (de) 1h-imidazol-5-carbonsaeurederivate.
SE7813226L (sv) Kvevebrohuvudsforeningar med antiallergiverkan jemte sett for deras framstellning
AR036074A1 (es) Derivados de aminoquinolina, las composiciones farmaceuticas que los contienen, el uso de los mismos para la preparacion de una composicion farmaceutica, un procedimiento para su preparacion y los intermediarios empleados en dicho procedimiento de preparacion
ES2096265T3 (es) Derivados aromaticos de hidroxiamidinas y su empleo como antagonistas del receptor leucotrieno b4.
ES2029879T3 (es) Procedimiento para producir derivados de aminas sustituidas.
ES2070002T3 (es) Composiciones terapeuticas a base de derivados de 1,2-ditiol-3-tiona.
PE47196A1 (es) DERIVADO 2,7-SUSTITUIDO DE OCTAHIDRO-1H-PIRIDO[1,2-a]PIRAZINA
AR248283A1 (es) Procedimiento para preparar nuevos derivados de 2'-halometiliden, 2'-etiniliden y 2'-etiniladenosina, inhibidores de la transmetilacion dependiente de adomet.
ES2095848T3 (es) Nuevos derivados de fosfolipidos y su utilizacion para la preparacion de medicamentos antiviricos.
ES2061447T3 (es) Compuestos con efecto nootropo, agentes que los contienen y su empleo en el tratamiento y la profilaxis de disfunciones cognitivas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 223420

Country of ref document: ES